Form 4: Kineta Director Disposes of All Holdings Following TuHURA Biosciences Merger

A Kineta, Inc. director has reported the disposition of all direct and indirect common stock and stock options, effective June 30, 2025, as a result of the company's merger with TuHURA Biosciences, Inc.

Summary

• Shawn Iadonato, a Director of Kineta, Inc., disposed of all his direct and indirect beneficial ownership in Kineta common stock and stock options.
• The disposition occurred on June 30, 2025, as a direct consequence of the Agreement and Plan of Merger between Kineta, Inc. and TuHURA Biosciences, Inc., initially dated December 11, 2024, and amended on May 5, 2025.
• Under the merger terms, each outstanding share of Kineta common stock was cancelled and converted into the right to receive 0.185298 shares of TuHURA Common Stock.
• Kineta common stockholders are also entitled to a pro rata portion of 1,129,884 additional shares of TuHURA Common Stock, to be issued six months post-merger closing, subject to adjustments for losses.
• Additionally, Kineta common stockholders have a right to a pro rata share of cash consideration from disposed asset payments related to legacy Kineta assets.
• All Kineta stock options with an exercise price greater than $0.64 were canceled and extinguished for no consideration at the effective time of the merger.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While options were canceled, the overall transaction represents a completed merger, which typically aims to create value for shareholders of the acquired entity through conversion into the acquiring company's stock and potential future considerations.

Positives

• The merger allows Kineta shareholders to receive shares in TuHURA Biosciences, providing continued equity participation in the combined entity.
• Kineta shareholders are eligible for additional TuHURA shares (1,129,884 shares in total) and potential cash consideration from legacy asset dispositions, offering further value post-merger.

Negatives

• Kineta stock options with an exercise price greater than $0.64 were canceled for no consideration, resulting in a loss of value for holders of these options.

Future Outlook

Kineta common stockholders are expected to receive a pro rata portion of 1,129,884 shares of TuHURA Common Stock approximately six months following the closing of the mergers, subject to adjustments. They also retain the right to a pro rata share of cash consideration from disposed asset payments related to legacy Kineta assets.

Industry Context

This filing reflects the finalization of a merger transaction, a common strategic move in the biotechnology and pharmaceutical sectors for companies seeking to consolidate operations, expand pipelines, or achieve greater market presence. Such mergers often involve the absorption of one entity into another, leading to the conversion or cancellation of the acquired company's securities.

Stakeholder Impact

• Shareholders of Kineta, Inc. have had their shares converted into TuHURA Common Stock, providing them with continued equity in the combined entity and potential future share distributions.
• Holders of Kineta stock options with exercise prices above $0.64 have had their options canceled without compensation, resulting in a loss of potential value.

Next Steps

• Issuance of pro rata portion of 1,129,884 shares of TuHURA Common Stock to Kineta shareholders approximately six months following the closing of the mergers.
• Distribution of pro rata share of cash consideration from disposed asset payments related to legacy Kineta assets to Kineta shareholders.

Key Dates

Keywords

SEC Form 4, Merger, Kineta Inc., TuHURA Biosciences Inc., Stock disposition, Stock options, Beneficial ownership, Corporate transaction, Biotechnology, Pharmaceuticals